XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Capital Stock (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Aug. 11, 2021
USD ($)
$ / shares
shares
Dec. 09, 2016
Dec. 31, 2021
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
shares
Jun. 30, 2021
$ / shares
Jun. 30, 2018
shares
Stock-based compensation disclosure              
Proceeds from issuance of common stock under stock plans | $       $ 620 $ 1,286    
Common stock, par value (in dollars per share) | $ / shares     $ 0.01 $ 0.01   $ 0.01  
Exercise price | $ / shares     6.60        
Warrant exercise price | $ / shares $ 0.01   0.01        
ESPP              
Stock-based compensation disclosure              
Aggregate number of common shares reserved for future issuance             2,000,000
Pre-Funded Warrants              
Stock-based compensation disclosure              
Exercise price | $ / shares     $ 6.59        
Threshold percentage of common stock owned that limits the number of warrants exercised 9.99            
Maximum percentage upon at least 61 days prior notice from the investor to the Company 19.99            
RA Capital Healthcare Fund, L.P. | Pre-Funded Warrants              
Stock-based compensation disclosure              
Pre-Funded warrants issued to purchase shares     16,000,000        
Redmile Group LLC | Pre-Funded Warrants              
Stock-based compensation disclosure              
Pre-Funded warrants issued to purchase shares     11,363,636        
Stock options              
Stock-based compensation disclosure              
Stock options granted to directors (in shares)       5,957,000      
Options exercised (in shares)       173,000      
Securities Purchase Agreement | Pre-Funded Warrants              
Stock-based compensation disclosure              
Proceeds from issuance of common stock under stock plans | $     $ 169,300        
Securities Purchase Agreement | RA Capital Healthcare Fund, L.P. | Pre-Funded Warrants              
Stock-based compensation disclosure              
Pre-Funded warrants issued to purchase shares 5,434,782            
Exercise price | $ / shares $ 5.51            
Aggregate gross proceeds | $ $ 29,700            
Compensation Policy for Non-Employee Directors | Stock options              
Stock-based compensation disclosure              
Stock options granted to directors (in shares)       352,000 300,000    
Non-employee directors-initial grant | Deferred share units              
Stock-based compensation disclosure              
Vesting period   3 years          
Non-employee directors-first anniversary | Deferred share units              
Stock-based compensation disclosure              
Vesting period   1 year